Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN) [Yahoo! Finance]
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: Yahoo! Finance
Fitzgerald maintained its Overweight rating on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $74. The firm said the stock has come under pressure because of concerns about competition, even though the company's cancer therapy, Carvykti, is still on track to grow around 100% year-over-year to reach nearly $2 billion in sales in 2025. Legend Biotech Corporation's (NASDAQ:LEGN) partner, Johnson & Johnson (NYSE:JNJ), has maintained its outlook for Carvykti to achieve peak sales over $5 billion in the growing multiple myeloma market. This forecast was reaffirmed at a post-American Society of Hematology meeting with analysts. According to estimates by Cantor Fitzgerald, Legend Biotech Corporation (NASDAQ:LEGN) is trading at an enterprise value to current sales multiple of roughly 3x and an enterprise value to peak sales multiple of approximately 1x. The research firm sees Legend Biotech Corporation (NASDAQ:LEGN) as “one of the best values in biotech” because of its pro
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Why The Legend Biotech LEGN Story Is Shifting As Carvykti And Competition Reframe Expectations [Yahoo! Finance]Yahoo! Finance
- Legend Biotech (NASDAQ:LEGN) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $75.00 price target on the stock.MarketBeat
- Remix Therapeutics Appoints Mythili Koneru, MD, PhD, as Chief Medical OfficerGlobeNewswire
LEGN
Sec Filings
- 1/14/26 - Form 6-K
- 1/12/26 - Form 6-K
- 12/29/25 - Form 144
- LEGN's page on the SEC website